Evidence map›Paper›PMID 18781828›Full record

ReviewExpert opinion on therapeutic targets2008

Chromatin-modifying enzymes as therapeutic targets--Part 1.

Brian R Keppler, Trevor K Archer

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Expert opinion on therapeutic targets, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
3.2field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 76 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Brian R KepplerNational Institute of Environmental Health Sciences, National Institutes of Health, North Carolina 27709, USA.
Trevor K Archer
National Institute of Environmental Health Sciences · US

Funding

Transcriptional Functions of Nuclear Receptors in Cancer CellsZIAES071006 · NIEHS · NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES · PI ARCHER, TREVOR KEITH · 2009 to 2025
$58.0M
Transcriptional Functions of Nuclear Receptors in Cancer CellsZ01ES071006 · NIEHS · NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES · PI ARCHER, TREVOR KEITH · 1999 to 2008
$6.9M
Intramural NIH HHS Z01 ES071006Intramural NIH HHS Z99 ES999999
6 · The paper itself

Abstract

backgroundDisease pathogenesis may result from genetic alterations and/or a more diverse group of epigenetic changes. While events such as DNA methylation are well established, there is significant interest in nucleosome remodeling, RNA interference and histone modifications, as mechanisms that underlie epigenetic effects. While genetic mutations are permanent, epigenetic changes can be transitory. The potential to reverse epigenetic changes has led to the development of therapeutic strategies targeting chromatin-modifying enzymes.

objectiveTo review the roles of chromatin-modifying enzymes in gene regulation and to highlight their potentials as therapeutic targets.

methodsThis review is based on recently published literature and online resources. RESULTS/

conclusionThis paper focuses on enzymes responsible for histone acetylation, deacetylation, methylation and demethylation, and their potential as targets for epigenetic therapies. A subsequent paper will do the same for enzymes responsible for histone phosphorylation, ubiquitylation, SUMOylation and poly-ADP-ribosylation as well as ATP-dependent nucleosome remodeling.

Indexed as

AnimalsChromatinEnzymesHistone AcetyltransferasesHistone Deacetylase InhibitorsHistone DeacetylasesHistone-Lysine N-MethyltransferaseHistone MethyltransferasesHumansProtein MethyltransferasesChromatinEnzymesHistone AcetyltransferasesHistone Deacetylase InhibitorsHistone DeacetylasesHistone-Lysine N-MethyltransferaseHistone MethyltransferasesProtein Methyltransferases

Identifiers

PMID18781828
PMCPMC2761090
OpenAlexW2166065186

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.